The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell-Mediated Immunotherapies.
Varghese S, Pramanik S, Williams LJ, Hodges HR, Hudgens CW, Fischer GM, Luo CK, Knighton B, Tan L, Lorenzi PL, Mackinnon AL, McQuade JL, Hailemichael Y, Roszik J, Peng W, Vashisht Gopal YN.
Varghese S, et al. Among authors: luo ck.
Mol Cancer Ther. 2021 Mar;20(3):500-511. doi: 10.1158/1535-7163.MCT-20-0430. Epub 2020 Dec 23.
Mol Cancer Ther. 2021.
PMID: 33361272
Free PMC article.